INTRODUCTION
============

As we write, Italy, Europe, and the entire world are facing one of the worst medical emergencies spanning centuries, the coronavirus disease 2019 (COVID-19) pandemia due to infection by SARS-CoV-2 virus. The early identification of risk factors for COVID-19 is an urgent medical need to provide the appropriate support to patients, including access to intensive care units.

Presently, Italy has one of the highest rate of SARS-CoV-2 infection in the world among large countries, with 371 cases per 100,000 people, one of the highest number of deaths and apparently also one of the highest mortality rates, 14.1% vs. an average value of 6.6% (as of May 16^th^, 2020, data from <https://coronavirus.jhu.edu/map.html>). These data may have different explanations, including: 1) the number of tests performed, 2) the structure of the population (Italy has the oldest population in Europe) \[https://ec.europa.eu/eurostat/data/database\], 3) the percentage of smokers, even though no significant association was found between smoking and severity of COVID-19 in a very recent study on the Chinese population \[[@r1]\], 4) the possible existence of a different virus strain \[[@r2]\], 5) a high population density in some hot spot areas of the infection, 6) the concentration of severe cases in a limited region of the country, potentially overwhelming the available intensive care units, 7) differences in environmental factors (e.g. air pollution), as well as 8) social factors, such as trust in the institutions and tendency to socialize \[[@r3]\]. However, there could also be some peculiar genetic characteristics of the Italian population that may have an impact on the susceptibility to viral infection, the disease severity, and the number of patients shedding huge amounts of virus.

What is unquestionable is a more severe course of the disease associated with older age and high number of comorbidities and with the male sex (male:female ratio in case fatality rate among Italians 1.75, data from the Italian National Institute of Health: <https://www.epicentro.iss.it/coronavirus/>), a feature shared with the 2003 SARS epidemic and MERS \[[@r4]--[@r6]\]. Indeed, while males and females have similar susceptibility to both SARS-CoV-2 and SARS-CoV, males are more prone to have higher severity and mortality, independently of age \[[@r4]\]. Among the many possible factors impacting on sex-related differences in disease manifestations, including the fact that females are known to mount a stronger immune response to viral infections compared to males due to more robust humoral and cellular immune responses \[[@r7]\], we decided to center our attention on possible genetic components, with a particular focus on the Italian population.

It was recently demonstrated that both angiotensin I converting enzyme 2 (ACE2) and the transmembrane protease, serine 2 (TMPRSS2) are crucial for SARS-CoV-2 entry into host cells \[[@r8], [@r9]\]. As previously described for SARS-CoV, ACE2 is the main receptor also for the spike (S) protein of SARS-CoV-2, mediating viral attachment to target cells. Moreover, both coronaviruses use TMPRSS2 for protein S priming, i.e. the cleavage of protein S at the S1/S2 and the S2' sites, allowing fusion of viral and cellular membranes \[[@r9]\]. Both genes have been proposed to modulate susceptibility to SARS-CoV \[[@r10], [@r11]\], and are good candidates to mediate sex-related effects: *ACE2* is located on the X chromosome, while *TMPRSS2* expression is responsive to androgen/estrogen stimulation \[[@r12]\]. Controversial data have been reported on the level of expression of *ACE2* in the lung of males and females \[[@r13]--[@r15]\], however, it must also be taken into account the effect of estrogen drop in postmenopausal life and the possible compensating effect of hormone replacement therapy in some females.

With this background, we searched for possible genetic components of COVID-19 severity among Italians by looking at expression levels and genetic variants in *ACE2* and *TMPRSS2*, two crucial genes for viral infection.

RESULTS AND DISCUSSION
======================

ACE2
----

For most X-chromosome genes, the double allelic dosage in females is balanced by the epigenetic silencing of one of the X chromosomes in early development \[[@r16]\]. However, the X-chromosome inactivation (XCI) is incomplete in humans and up to one third of genes are expressed from both alleles, with the degree of XCI escape varying between genes and individuals \[[@r17]\]. *ACE2* is one of the genes escaping X inactivation, but it belongs to a subgroup of X-chromosome genes escaping XCI showing an uncharacteristically heterogeneous pattern of male-female expression, with higher expression in males in several tissues \[[@r13]\]. Specifically concerning the lung, a recent analysis on published expression data, reported a substantial similar level of *ACE2* transcript in males and females \[[@r14]\], however, another study, using single-cell sequencing, found a higher expression of *ACE2* in Asian males \[[@r15]\]. [Figure 1](#f1){ref-type="fig"} reports data on *ACE2* mRNA expression levels in the lung as retrieved from the largest datasets available in the literature; no substantial differences were found between males and females, nor between younger and older females, thus confirming what already observed by Cai and colleagues \[[@r14]\].

![***ACE2* expression levels.** All panels show *ACE2* mRNA expression levels in human normal lung samples stratified according to sex (or on sex and age). On left panels, data were retrieved for a total of 578 RNAseq experiments from the GTex repository. Expression levels are reported as transcripts per kilobase million (TPM). On the right, data were collected from two different datasets (GSE66499 and GSE19804) from the GEO database. Expression levels are reported as normalized signal intensities. P values were calculated by using either the Kruskal-Wallis or the student t test, using the R software (<https://www.r-project.org/>).](aging-12-103415-g001){#f1}

Another possible sex-related effect might be due to the fact that males are hemizygous for the gene, therefore, in the presence of an *ACE2* allelic variant increasing disease susceptibility or severity, males will have all cells expressing the risk variant. Based on this hypothesis, we looked into the genetic variation in *ACE2*. A recent manuscript explored this same topic in different populations using data from public databases \[[@r18]\]. However, a specific analysis of the Italian population is Iacking.

We have therefore exploited the available data on 3,984 exomes obtained from an Italian cohort representative of the whole country \[[@r19], [@r20]\] to extract the variants in exons and splice junctions of *ACE2*. Variants were filtered for quality and classified according to their predicted effect at protein level and on splicing. Concerning rare variants (i.e. those with a minor allele frequency, MAF, \<1%; to be used in burden tests), we considered only null variants, abolishing or significantly impairing protein production (nonsense, out-of-frame ins/dels, and splicing variants), and missense variants predicted to be deleterious or possibly deleterious by all the 5 prediction algorithms used (see [Supplementary Methods](#SD1){ref-type="supplementary-material"}, paragraph "Definition of disrupting variants and statistical analysis"). Concerning common variants (i.e., MAF\>5%), all were retained for comparing their frequency with those of the European (non Finnish) and East Asian populations, retrieved from the GnomAD repository.

No significant differences in the burden of rare deleterious variants were observed comparing the Italian population with Europeans and East Asians ([Table 1A](#t1a){ref-type="table"}). Concerning common exonic variants, the only striking difference, as also noticed by Cao and colleagues \[[@r18]\], was observed for the single nucleotide polymorphism (SNP) rs2285666 (also called G8790A), with the frequency of the rare A allele being 0.2 in Italians and Europeans, and 0.55 in East Asians (uncorrected P=2.2\*10-16 for difference in Italians vs East Asians; corrected P=7.9\*10-15; [Table 1B](#t1b){ref-type="table"}). This variant was extensively studied as a potential risk factor for hypertension, type 2 diabetes, and coronary artery disease \[[@r21], [@r22]\], hence possibly constituting a predisposing factor also for the comorbidities observed in COVID-19 patients. A single paper reports the association of the three rs2285666 genotypes with ACE2 protein level measured in serum by ELISA, with the A/A genotype having an expression level almost 50% higher than the G/G genotype, while heterozygous G/A individuals had intermediate levels \[[@r23]\]. Given the position of the variant, at nucleotide +4 in the donor splice site of intron 3 (c.439+4G\>A), we calculated the predicted effect on splicing and indeed the substitution of G with an A is predicted to increase the strength of the splice site of about 9.2% (calculation made through the Human Splicing Finder v.3.1 webtool, <http://www.umd.be/HSF/>), consistently with the higher level of ACE2 protein in serum. It would be crucial to compare the frequency of this variant with *ACE2* expression in the lung and with susceptibility to viral infection and severity of COVID-19 manifestations. Of note, no eQTL for *ACE2* in the lung has been described so far in the GTEx database, and investigations on this topic are recommended.

###### Burden of rare mutations in the *ACE2* gene in different populations.

  ---------------- --------------- -------- ------------- --------- --------- ---------
  **Population**   **N alleles**   **T1**   **Freq T1**   **ITA**   **EUR**   **EAS**
  ITA              4422            7        0.0016        \-        P=0.518   P=0.974
  EUR              92545           200      0.0022        P=0.518   \-        P=0.077
  EAS              14840           21       0.0014        P=0.974   P=0.077   \-
  ---------------- --------------- -------- ------------- --------- --------- ---------

Total allele counts, carrier allele counts, and carrier frequencies are shown; only deleterious variants with MAF less than 1% were considered in the burden analysis. The 'deleterious' set is defined by missense variations predicted to be possibly damaging by all the 5 algorithms used (LRT score, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 HumVar, and SIFT), and loss-of-function variants (nonsense, frameshift, and splicing variants affecting the donor/acceptor sites).

P values are presented as non-corrected; the number of statistical comparisons performed in [Tables 1A](#t1a){ref-type="table"}, [1B](#t1b){ref-type="table"}, [2A](#t2a){ref-type="table"}, and [2B](#t2b){ref-type="table"} is collectively of 24, thus lowering the threshold for significance at P=0.0021 (Bonferroni threshold).

T1: alleles carrying damaging variants; Freq T1: frequency of T1 allele; ITA: Italian population; EUR: European population; EAS: East Asian population.

###### Common exon variants in the *ACE2* gene in different populations.

  ---------------- ----------------- ---------------------- -------------- ---------------------- -------------- ---------------------- -------------- ---------------- ---------------- ----------------
  **Variant ID**   **Consequence**   **A1/N alleles ITA**   **Freq ITA**   **A1/N alleles EUR**   **Freq EUR**   **A1/N alleles EAS**   **Freq EAS**   **ITA Vs EUR**   **ITA Vs EAS**   **EUR Vs EAS**
  rs2285666        c.439+4G\>A       909/4408               0.206          17240/86164            0.200          7336/13387             0.548          0.331            **P\<2.2e-16**   **P\<2.2e-16**
  rs35803318       p.Val749Val       235/4422               0.053          3935/88946             0.044          0/13918                0.0            P=0.0058         **P\<2.2e-16**   **P\<2.2e-16**
  ---------------- ----------------- ---------------------- -------------- ---------------------- -------------- ---------------------- -------------- ---------------- ---------------- ----------------

Total allele counts, carrier allele counts, and carrier frequencies are shown; only variants with MAF more than 5% were considered.

P values are presented as non-corrected; the number of statistical comparisons performed in [Tables 1A](#t1a){ref-type="table"}, [1B](#t1b){ref-type="table"}, [2A](#t2a){ref-type="table"}, and [2B](#t2b){ref-type="table"} is collectively of 24, thus lowering the threshold for significance at P=0.0021 (Bonferroni threshold). Significant P values are indicated in bold.

A1: alleles carrying variants; Freq A1: frequency of A1 allele; ITA: Italian population; EUR: European population; EAS: East Asian population.

TMPRSS2
-------

*TMPRSS2* is a gene well known to oncologists as genetic rearrangements producing a fusion between *TMPRSS2* and *ERG* (or, more rarely, other members of the ETS family) are the most frequent genetic lesions in prostate cancer patients \[[@r24]\]. As *TMPRSS2* is an androgen responsive gene, the fusion results in androgen dependent transcription of ERG in prostate tumor cells. Therefore, we can hypothesize that males might have higher *TMPRSS2* expression also in the lung, which might improve the ability of SARS-CoV-2 to enter cells by promoting membrane fusion. Looking into GTEx and GEO data, the overall expression of *TMPRSS2* in the lung is only slightly increased in males (P=0.029; [Figure 2A](#f2){ref-type="fig"}). However, *TMPRSS2* expression is also promoted by estrogens \[[@r12]\], and therefore the situation might be different when considering individuals above 60 years, who are at higher risk of fatal events due to COVID-19, as in this group females will all be postmenopausal. According to this hypothesis, we checked the expression of the gene in lungs of males and females at different ages, but no substantial differences emerged between males and females (neither below, nor above 60 years of age; data not shown).

![***TMPRSS2* expression levels and eQTLs.** (**A**) Both panels show *TMPRSS2* mRNA expression levels in human normal lung samples stratified according to sex. On the left, data were retrieved for a total of 578 RNAseq experiments from the GTex repository. Expression levels are reported as transcripts per kilobase million (TPM). On the right, data were collected for a total of 170 microarray experiments from the GEO database. Expression levels are reported as normalized signal intensities. P values were calculated by using either the Kruskal-Wallis or the student t test. (**B**) Screenshot from the UCSC Genome browser (<http://genome.ucsc.edu/>; GRCh37/hg19) highlighting the *TMPRSS2* region (coordinates chr21: 42,835,000-42,905,000). The panel shows the following tracks: i) the ruler with the scale at the genomic level; ii) chromosome 21 nucleotide numbering; iii) the UCSC RefSeq track; iv) enhancers (grey and red bars) from GeneHancer database; v) interactions (curved lines) connecting GeneHancer regulatory elements and genes: all curved lines converge towards the androgen-responsive enhancer for the *TMPRSS2* gene described by Clinckemalie and colleagues \[[@r29]\].](aging-12-103415-g002){#f2}

Finally, we explored genetic variation in *TMPRSS2* in search of variants, possibly already annotated as eQTL in the lung, which might have an impact on the serine protease expression as well as on its catalytic activity. Again, we used the available Italian exome data, as well as data deposited in GnomAD \[[@r25]\].

Firstly, we looked at the overall burden of deleterious rare variants, using the variant classification described above. Italians had a nominally significant decrease in the burden of deleterious variants compared to Europeans (uncorrected P=0.039, not significant after correction for multiple testing; [Table 2A](#t2a){ref-type="table"}). This decrease was even more evident for the East Asian population (corrected P=8.6\*10-4); however, in this case, we must consider that the number of individuals over 65 years of age in Italy is more than double the one in the Hubei province (22.7 vs. 10%, respectively) and this is a major determinant of disease lethality.

###### Burden of rare mutations in the *TMPRSS2* gene in different populations.

  ---------------- --------------- -------- ------------- --------------- --------------- ---------------
  **Population**   **N alleles**   **T1**   **Freq T1**   **ITA**         **EUR**         **EAS**
  ITA              7968            30       0.0038        \-              P=0.039         **P=3.6e-05**
  EUR              129920          726      0.0056        P=0.039         \-              **P=9.8e-16**
  EAS              19979           25       0.0013        **P=3.6e-05**   **P=9.8e-16**   \-
  ---------------- --------------- -------- ------------- --------------- --------------- ---------------

Total allele counts, carrier allele counts, and carrier frequencies are shown; only deleterious variants with MAF less than 1% were considered in the burden analysis. The 'deleterious' set is defined by missense variations predicted to be possibly damaging by all the 5 algorithms used (LRT score, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 HumVar, and SIFT), and loss-of-function variants (nonsense, frameshift, and splicing variants affecting the donor/acceptor sites).

P values are presented as non-corrected; the number of statistical comparisons performed in [Tables 1A](#t1a){ref-type="table"}, [1B](#t1b){ref-type="table"}, [2A](#t2a){ref-type="table"}, and [2B](#t2b){ref-type="table"} is collectively of 24, thus lowering the threshold for significance at P=0.0021 (Bonferroni threshold). Significant P values are indicated in bold.

T1: alleles carrying damaging variants; Freq T1: frequency of T1 allele; ITA: Italian population; EUR: European population; EAS: East Asian population.

Focusing specifically on common exonic variants, 4 SNPs showed significantly (P\<2.2\*10-16) different frequencies when comparing the Italian population with East Asians (and with Europeans) ([Table 2B](#t2b){ref-type="table"}); 3 of them are synonymous variants, whereas one is the missense substitution p.Val160Met, which impacts on a residue far from the serine protease catalytic triad. This variant was previously found significantly associated with genomic rearrangements involving *TMPRSS2,* with the risk of prostate cancer \[[@r26]\] and with shorter time to prostate cancer diagnosis for high-risk patients \[[@r27]\].

###### Common exon variants in the *TMPRSS2* gene in different populations.

  ---------------- ----------------- ---------------------- -------------- ---------------------- -------------- ---------------------- -------------- ---------------- ---------------- ----------------
  **Variant ID**   **Consequence**   **A1/N alleles ITA**   **Freq ITA**   **A1/N alleles EUR**   **Freq EUR**   **A1/N alleles EAS**   **Freq EAS**   **ITA Vs EUR**   **ITA Vs EAS**   **EUR Vs EAS**
  rs2298659        p.Gly259Gly       1388/7968              0.174          28744/122880           0.234          5179/19478             0.266          **P\<2.2e-16**   **P\<2.2e-16**   **P\<2.2e-16**
  rs17854725       p.Ile256Ile       4131/7968              0.518          67712/122814           0.551          2544/19604             0.130          **P=1.16e-08**   **P\<2.2e-16**   **P\<2.2e-16**
  rs12329760       p.Val160Met       1387/7968              0.174          29831/128604           0.232          7651/19934             0.384          **P\<2.2e-16**   **P\<2.2e-16**   **P\<2.2e-16**
  rs3787950        p.Thr75Thr        889/7968               0.112          9864/127666            0.077          2905/19600             0.148          **P\<2.2e-16**   **P=1.39e-15**   **P\<2.2e-16**
  ---------------- ----------------- ---------------------- -------------- ---------------------- -------------- ---------------------- -------------- ---------------- ---------------- ----------------

Total allele counts, carrier allele counts, and carrier frequencies are shown; only variants with MAF more than 5% were considered.

P values are presented as non-corrected; the number of statistical comparisons performed in [Tables 1A](#t1a){ref-type="table"}, [1B](#t1b){ref-type="table"}, [2A](#t2a){ref-type="table"}, and [2B](#t2b){ref-type="table"} is collectively of 24, thus lowering the threshold for significance at P=0.0021 (Bonferroni threshold). Significant P values are indicated in bold.

A1: alleles carrying variants; Freq A1: frequency of A1 allele; ITA: Italian population; EUR: European population; EAS: East Asian population.

Concerning eQTLs, a number of variants significantly impacting on *TMPRSS2* expression in the lung (GTex data) are reported in the 3' region of the gene ([Figure 2B](#f2){ref-type="fig"}). In [Table 2C](#t2c){ref-type="table"}, a list of the most significant (P\<1\*10-8), together with their GnomAD frequencies in the East Asian and European populations, are reported. As for the Italian frequencies, we took advantage of the genome-wide association study (GWAS) performed on the above-described cohort (for a total of 3,284 individuals) \[[@r28]\]; in this case, we had to infer genotype frequencies by an imputation approach (for details, see Supplementary Methods). Interestingly, all these eQTLs appear to have extremely different frequencies among populations. In particular, 2 different haplotypes can be inferred from frequency data:

###### eQTL variants in the *TMPRSS2* gene in different populations.

  ---------------- ------------ -------------- -------------- -------------- -------------- ---------------- ---------------- ----------------
  **Variant ID**   **P GTEx**   **NES GTEx**   **Freq ITA**   **Freq EUR**   **Freq EAS**   **ITA vs EUR**   **ITA vs EAS**   **EUR vs EAS**
  rs463727         5.0e-10      0.12           0.44           0.46           0.0051         P=0.038          **P\<2.2e-16**   **P\<2.2e-16**
  rs2070788        8.9e-9       -0.11          0.55           0.53           0.66           P=0.003          **P=4.7e-15**    **P\<2.2e-16**
  rs9974589        7.4e-9       -0.12          0.55           0.53           0.66           P=0.002          **P=3.3e-15**    **P\<2.2e-16**
  rs34624090       9.2e-9       0.12           0.43           0.45           0.0051         P=0.005          **P\<2.2e-16**   **P\<2.2e-16**
  rs7364083        3.3e-9       -0.12          0.56           0.53           0.65           **P=8.7e-05**    **P=1.9e-10**    **P\<2.2e-16**
  rs55964536       1.9e-9       0.12           0.46           0.49           0.0045         **P=4.6e-04**    **P\<2.2e-16**   **P\<2.2e-16**
  rs734056         1.3e-9       0.12           0.47           0.49           0.0051         P=0.030          **P\<2.2e-16**   **P\<2.2e-16**
  rs4290734        8.3e-10      0.12           0.47           0.49           0.0051         P=0.019          **P\<2.2e-16**   **P\<2.2e-16**
  rs34783969       3.9e-10      0.12           0.47           0.49           0.0051         P=0.027          **P\<2.2e-16**   **P\<2.2e-16**
  rs11702475       8.4e-10      0.12           0.47           0.49           0.0046         P=0.015          **P\<2.2e-16**   **P\<2.2e-16**
  rs35899679       7.8e-9       0.11           0.44           0.46           0.0051         P=0.004          **P\<2.2e-16**   **P\<2.2e-16**
  rs35041537       3.6e-9       0.12           0.44           0.47           0.0051         **P=8.6e-04**    **P\<2.2e-16**   **P\<2.2e-16**
  ---------------- ------------ -------------- -------------- -------------- -------------- ---------------- ---------------- ----------------

P values are presented as non-corrected; the number of statistical comparisons performed in [Table 2C](#t2c){ref-type="table"} is collectively of 36, thus lowering the threshold for significance at P=0.0013 (Bonferroni threshold). Significant P values are indicated in bold.

NES: normalized effect size; Freq: frequency of the minor allele; ITA: Italian population; EUR: European population; EAS: East Asian population.

1.  A frequent "European" haplotype (composed at least of SNPs rs463727, rs34624090, rs55964536, rs734056, rs4290734, rs34783969, rs11702475, rs35899679, and rs35041537), which is totally absent in the Asian population. Interestingly, this haplotype has been functionally linked to another eQTL (rs8134378), located at a known androgen-responsive enhancer for *TMPRSS2*, 13 kb upstream of the *TMPRSS2* transcription start site \[[@r29]\] ([Figure 2B](#f2){ref-type="fig"}). Hence, this haplotype is expected to up regulate *TMPRSS2* gene expression in an androgen-specific way.

2.  A second haplotype, predicted to be associated with higher *TMPRSS2* expression, is characterized by 3 SNPs (rs2070788, rs9974589, rs7364083), whose MAF is significantly increased in Europeans (9% increase in Italians respect to East Asians, corrected P\<6.8\*10^-9^). Importantly, a small-scale GWAS, comparing the distribution of genetic variants in severe and mild cases of patients with A(H1N1)pdm09 influenza, identified rs2070788 as being associated with increased risk to both human A(H7N9) and severe A(H1N1)pdm09 influenza \[[@r11]\]. Of note, also in A(H7N9) influenza, the proportion of male patients was more than double that of female patients \[[@r30]\].

LIMITATIONS AND CONCLUSIONS
===========================

We are aware of the limitations of our study: first of all we focused our attention only to two candidate genes identified on the basis of their crucial role in viral infection and on the a priori probability that they might mediate sex-specific effects. A number of other X-linked genes (such as *IL13, IL4, IL10, XIST, TLR7, FOXP3)* and Y-linked genes (*SRY*, *SOX9*) may underlie sexually dimorphic immune responses \[[@r31]\]. Moreover, the number of non-genetic determinants of sex-biased severity and case fatality rates is huge and probably has to do not only with sex differences in both innate and adaptive immune responses \[[@r7]\], but also with gender and cultural habits in different countries. In particular, important gender-related factors might concern the social role of women (job, maternal and childcare role), the propensity to smoke, the hand hygiene compliance, as well as differences in the impact of the social role of women in the different countries.

In conclusion, we have explored possible genetic components impacting on COVID-19 severity, focusing on effects mediated by *ACE2* and *TMPRSS2* genes in the Italian population. From available data, it seems unlikely that sex-differences in *ACE2* levels can explain sex differences in disease severity. However, it remains to be evaluated if changes in *ACE2* levels in the lung correlate with susceptibility and severity of SARS-CoV-2 infection. Experimental data from patients with different disease manifestations are urgently needed. Among the analyzed hypotheses, the most interesting signals refer to sex-related differences in *TMPRSS2* expression and in genetic variation in *TMPRSS2*. In particular, we identified an exonic variant (p.Val160Met) and 2 distinct haplotypes showing profound frequency differences between East Asians and Italians. The rare alleles of these haplotypes, all predicted to induce higher levels of *TMPRSS2*, are more frequent in the Italian than in the East Asian population; in one case, the haplotype could be regulated through androgens, thus possibly explaining the sex bias in COVID-19 severity, in the other case, a SNP belonging to the haplotype has been associated with increased susceptibility to influenza, possibly related to a higher susceptibility in Italians and Europeans.

Our data, beside suggesting possible explanations for the unusually high, relative to known data, lethality rates among Italians, provide reference frequencies in the general Italian population for candidate variants that can be compared to genetic data from patients infected by SARS-CoV-2 with different disease manifestations, as soon as they will be available on large numbers of patients. These studies will hopefully be of help in predicting the individual risk of infection and susceptibility to CoV-2 and in recognizing in advance infected individuals being at higher risk of poor prognosis.

MATERIALS AND METHODS
=====================

Gene expression data
--------------------

Expression data for *ACE* and *TMPRSS2* genes were obtained through the: 1) genotype-tissue expression (GTEx) database (<https://gtexportal.org/home/>), which was also used to extract quantitative trait loci (eQTLs) for the two genes (all data based on RNAseq experiments); and 2) Gene Expression Omnibus (GEO) repository (<https://www.ncbi.nlm.nih.gov/geo/>). In particular, two GEO datasets were extracted and analyzed: 1) GSE66499, reporting microarray data on 152 normal lung samples from Caucasian individuals; 2) GSE19804, reporting microarray data on 60 normal lung samples from Taiwanese females (see also Supplementary Methods, paragraph "Datasets and statistical power estimations").

Genetic data
------------

Genetic data for general European and East Asian populations were retrieved through the GnomAD repository, which contains data on a total of 125,748 exomes and 71,702 genomes (<https://gnomad.broadinstitute.org/>).

As for Italians, details on whole-exome sequencing (on 3,984 individuals) and genome-wide microarray genotyping (on 3,284 individuals) of the analyzed cohort are specified elsewhere \[[@r19], [@r20], [@r28]\], as well as in Supplementary Methods (paragraphs "Sequencing" and "Datasets and statistical power estimations"). Imputation procedures are detailed in Supplementary materials (paragraph "Dataset imputation\>").

Statistical analysis
--------------------

Expression levels were compared by using either the Kruskal-Wallis test (RNAseq data) or the student t test (microarray data). Allele frequencies were compared using the chi square test. All calculations were performed using the R software (<https://www.r-project.org/>). P values are presented as non-corrected for multiple testing, but the Bonferroni-corrected threshold of significance is indicated below each set of comparisons presented in Tables. Power calculations have been described in Supplementary Methods (paragraph "Datasets and statistical power estimations").
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